This report was first published by Endpoints News. To see the original version, click here
Eli Lilly surpassed analysts’ expectations for 2025 and fourth-quarter revenues on Wednesday morning, and anticipates a large increase in revenue this year. It marks a sharp juxtaposition to its main rival Novo Nordisk, which expects to shrink in 2026.
Lilly said it pulled in $19.29 billion in the last quarter of 2025, thanks to $11.66 billion from its tirzepatide franchise. Analysts had expected $17.8 billion for the quarter. Full-year 2025 revenues came in at $65.17 billion, well above the $63.9 billion that analysts projected and the $63.5 billion that Lilly predicted in October.
您已阅读23%（678字），剩余77%（2252字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。